Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of nemolizumab in prurigo nodularis
2019-004294-13Phase 3Active
- Sponsor
- Galderma
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nemolizumab in prurigo nodularis (PN), sponsored by Galderma. Primary endpoint: Incidence and severity of adverse events. Started Apr 2020; status: active.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2019-004294-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004294-13.